Basic Study
Copyright ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Transplantation. Sep 10, 2018; 8(5): 156-166
Published online Sep 10, 2018. doi: 10.5500/wjt.v8.i5.156
Interaction of immunosuppressants with HCV antivirals daclatasvir and asunaprevir: combined effects with mycophenolic acid
Petra E de Ruiter, Yashna Gadjradj, Robert J de Knegt, Herold J Metselaar, Jan NM Ijzermans, Luc JW van der Laan
Petra E de Ruiter, Yashna Gadjradj, Jan NM Ijzermans, Luc JW van der Laan, Department of Surgery, Erasmus MC-University Medical Center, Rotterdam CN 3015, the Netherlands
Robert J de Knegt, Herold J Metselaar, Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Rotterdam CN 3015, the Netherlands
Author contributions: de Ruiter PE participated in sample and data collection and analysis and writing of the manuscript; Gadjradj Y participated in sample and data collection and analysis; de Knegt R participated in the design of the study; Metselaar HJ participated in the design of the study; IJzermans JNM participated in the design of the study; van der Laan LJW participated in the design of the study and writing of the manuscript.
Conflict-of-interest statement: All authors have no conflicts of interest to report.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Luc JW van der Laan, PhD, Associate Professor, Laboratory of Experimental Transplantation and Intestinal Surgery, Department of Surgery, Erasmus MC-University Medical Center, Room Na1006, Wytemaweg 80, Rotterdam CN 3015, the Netherlands. l.vanderlaan@erasmusmc.nl
Telephone: +31-10-7037557 Fax: +31-10-7032793
Received: April 24, 2018
Peer-review started: April 24, 2018
First decision: June 6, 2018
Revised: June 14, 2018
Accepted: June 27, 2018
Article in press: June 27, 2018
Published online: September 10, 2018
Processing time: 136 Days and 16.6 Hours
Core Tip

Core tip: Since 2013, several new generation direct acting antivirals (DAAs) have been approved for the treatment of hepatitis C virus (HCV), including daclatasvir (DCV) and asunaprevir (ASV). Although a few reports investigated the effectivity of DAAs after liver transplantation, the effects of specific immunosuppressants on the antiviral efficacy remain largely unknown. We investigated the effect of the immunosuppressants on the antiviral action of DCV and ASV in two in vitro models for HCV. We observed that none of the immunosuppressants negatively affected the antiviral activity of these DAAs, and that mycophenolic acid has an additive effect on their antiviral action.